

RETINOBLASTOMA AND ORBITAL DAY

Saturday, April 5th

RETINOBLASTOMA

Chairs: Dan Gombos, Guy Negretti

9.00 | L | Neovascular Glaucoma as a Predictor of Retinoblastoma High-Risk Histopathology in an International Multicentre Study (Guy Negretti)

9.15 | L | A retrospective study on adjuvant chemotherapy in retinoblastoma: validation of the new recommendation against treatment for pT2a tumors based on the 8th AJCC (Hind M. Alkatan)

9.30 | L | The AMCC program in sub-Saharan Africa to improve the management of retinoblastoma (Denis Malaise)

9.45 | L | Impact of High-Risk Histopathological Features on Outcomes in Unilateral Retinoblastoma: Massive Choroidal Invasion, Retrolaminar Optic Nerve Invasion (Shahar Frenkel)

10.00 | L | Sequencing of RB1 in previously untested survivors of retinoblastoma (Tero T. Kivelä)

10.15 | S | Adjuvant high dose intravitreal topotecan in the management of macular retinoblastoma in a 2-month-old (Dan Gombos)

10.20 | S | Recurrent ciliochoroidal retinoblastoma in a 9-year-old with 13q deletion (Dan Gombos)

10.25 | S | Black Posterior Vitreous Detachment: An 8-year Historical Cohort (Vicktorija Vishnevskia-Dai)

10.30 | Coffee break

ORBIT

Chairs: Martina Angi, Daniel Briscoe

11.00 | L | Rare Paediatric Orbital Tumors (Daniel Briscoe)

11.15 | L | Survival in Merkel Cell Carcinoma (Guy Missotten)

11.30 | L | Neoadjuvant systemic treatment for locally advanced conjunctival melanoma (Martina Angi)

11.45 | L | Fine Needle Aspiration Biopsy and Flow Cytometry in Orbital non-Hodgkin Lymphomas (Raffaele Parrozzani)

12.00 | L | Long-term outcomes after multidisciplinary treatment for pediatric orbital rhabdomyosarcoma (Nur Khatib)

12.15 | L | Topical 5-Fluorouracil 1% in the management of ocular surface squamous neoplasia (Jessica Sergenti)

12.30 | S | A rare case of lacrimal gland adenoid cystic carcinoma (Maria Olteanu)

12.35 | S | Palpebral and conjunctival sebaceous carcinomas, a challenging diagnosis: about 3 cases (Laura Ninet)

12.40 | S | Conservative treatment of conjunctival dedifferentiated liposarcoma (Alice Carra)

12.45 | S | Case Presentation - Management of Benign Fibrous Histiocytoma of the Conjunctiva (Peter Skov Jensen)

12.50 | S | International Validation of Rapidly Progressing Proptosis and Vision Loss in an 84-Year Old: A Diagnostic Challenge (Yamini Krishna)

12.55 | S | Iris extension of an invasive conjunctival squamous cell carcinoma treated by proton beam therapy: a case report (Solène Kairis)

13.00 | Lunch

14.00 | K | Single-cell, molecular, and functional landscapes of melanoma converge on clinically actionable features Mitchell Levesque, University of Zurich, Switzerland

OTHER TUMORS

Chairs: Shahar Frenkel, Doris Hadjistilianou

14.45 | L | Optic pathway Glioma in pediatric patients treated with MEK inhibitors and standard chemotherapy: visual, tomographic, and clinical outcomes (Paola Valente or Federico Carlucci)

15.00 | L | Epidemiology, diagnosis, and outcomes of ocular (choroidal and orbital) metastases: retrospective cohort study from a tertiary center (Arad Dotan)

15.15 | L | Prognostic value of BAP1 and PRAME immunohistochemistry in iris melanoma (Mette Marie Bagger Sjøel)

15.45 | L | Prevalence and Characteristics of Choroidal Nevi in 34,793 individuals. A nation-wide study based on optician fundus photography (Carsten Faber)

16.00 | Coffee break

COMPLICATIONS OF THERAPY

Chairs: Alexandre Matet, Jessica Sergenti

16.30 | L | Role of aspirin in preventing carboplatin induced vascular thrombosis following intra-arterial chemotherapy (IAC) (Dan Gombos)

16.45 | L | Evidence of inflammatory mechanisms in an animal model of radiation retinopathy (Alexandre Matet)

17.00 | S | Diffuse fundus hypopigmentation associated with immunotherapy for metastatic melanoma (Jørgen Krohn)

17.05 | S | Anterior chamber infiltration of CAR T-cells (Vicktorija Vishnevskia-Dai)

17.10 | S | Rare tumors and endless stories (Doris Hadjistilianou)

17.15 | S | PVF associated with...? (Doris Hadjistilianou)

17.20 | L | Uveal melanoma management, the role of multidisciplinary ocular and periocular cancer meetings over a 2-year period (Federico Giannuzzi)

17.30 | Closing remarks and goodbye



59th

OPHTHALMIC ONCOLOGY GROUP MEETING

3-6 April
2025

Teatro di Strada Nuova

Palazzo Rosso, Via Garibaldi, 18
Entrance from Vico Boccanegra

CONFERENCE SECRETARIAT



Piazza Manin 2B R - 16122 Genova
tel: 010 888871 | e-mail: info@ggallery.it
sito: www.gallerygroup.it

aura



L = long presentation
(15 min incl. discussion)

LEGEND:
S = short presentation
(5 min incl. discussion)

K = keynote lecture

EXPERIMENTAL DAY

Thursday, April 3rd

09.00 | Welcome local organizers
Welcome president OOG

YOUNG INVESTIGATORS NETWORK (YIN) SESSIONS: EXPERIMENTAL APPROACHES

09:20 | Welcome YIN representatives

UVEAL MELANOMA, TUMOR IMMUNOLOGY

Chairs: Denis Malaise, Antonia Joussea

9.30 | L | Tumour progression shows decrease in PD-L1 expression in matched metastases/primary uveal melanomas (Rob Verdijk)

9.45 | L | Uveal Melanoma cells suppress the antitumor response of Natural Killer lymphocytes (Alessandra Loda)

10.15 | L | Immune Landscape of Uveal Melanoma (Antonia Joussea)

10.30 | Coffee break

PHYSICS IN OCULAR ONCOLOGY

Chairs: Edoardo Midena, Jan-Willem Beenakker

11.00 | L | Validation of the geometric eye model used in ocular proton therapy planning (Jan-Willem Beenakker)

11.15 | L | Tracking Treatment Effects in Radiation Macular Edema using OCT Biomarkers: an Artificial Intelligence Approach (Edoardo Midena)

11.30 | L | Quantitative perfusion-weighted magnetic resonance imaging for intraocular lesions (Iris Mulder)

11.45 | L | Results of training the neural network in detecting small choroidal melanocytic lesions and associated subretinal fluid on OCT scans (Emilia Zwolińska)

12.15 | L | Development of a validation setup for fusing fundus photographs and MRI (Corné Haasjes)

12.30 | L | Impact of Anterior Segment Swept-Source Optical Coherence Tomography for the Diagnosis of Conjunctival Tumors (Sacha Nahon-Estève)

12.45 | L | Estimating uveal melanoma volume with ellipsoid tumour models (Lisa Klaassen)

13.00 | Lunch

14.00 | K | Personalized Cellular Immunotherapy for Metastatic Uveal Melanoma
Udai S. Kammula - University of Pittsburgh, Pittsburgh, USA

EXPERIMENTAL UVEAL MELANOMA

Chairs: Ulrich Pfeffer, Ann Schalenbourg

14.45 | L | The p53 isoforms as modifiers of p53 tumor suppressor ability in uveal melanoma (Yari Ciribilli)

15.00 | L | Analysis of proliferation in uveal melanoma eyes after secondary enucleation for indications other than clinical relapse (Julien Schaller)

15.15 | L | Generation of monosomy 3 in the proliferating uveal melanoma cells under hyperglycemia (Aysegül Tura)

15.30 | L | Differential Responses of Retinal Cells and Uveal Melanoma Organoids to Proton Irradiation (Susanne Wolf)

15.45 | L | Uveal Melanoma: Bridging Research with Effective, Reliable, and Immunocompetent Mouse Models (Zeinab El Rashed)

16.00 | Coffee break

UVEAL MELANOMA BIOLOGY

Chairs: Natasha van Poppelers/Tero Kivela

16.30 | L | Subclass dependent biomarkers involved in uveal melanoma progression, cell plasticity and metastatic risk (Erwin Brosens)

16.45 | S | Heterogeneity of p53 functionality in uveal melanoma: do p53 isoforms have a role (Samuele Brugnara)

16.50 | S | Limbal stem cell transplantation for severe limbal stem cell deficiency in ocular oncology (Ekaterina Sokolenko)

16.55 | S | Targeting Epigenetic and Metabolic Pathways in Uveal Melanoma (Michela Croce)

17.00 | OOG Business Meeting

OCULAR MELANOMA DAY

Friday, April 4th

UVEAL MELANOMA MOLECULAR STUDIES

Chairs: Alexandre Moulin, Raffaele Parrozzani

8.30 | L | Retino-invasive uveal melanoma: a spatial transcriptomic study (Alexandre Moulin)

8.45 | L | Tumor-intrinsic effect of PIK3CD in uveal melanoma and implication in the clinical evaluation of the PI3Kd inhibitor Roginolisib (Michael Lahn)

9.00 | L | Somatic genomic prognostication of uveal melanoma: long-term study on metastatic risk and survival (Anna Giulia Di Dario)

9.15 | L | Prognostic Significance of Tumor Histological Type, BAP1 Gene Expression, and Tumor Environment (TILs/TAMs) in Uveal Melanoma: What is More Important? (Elena Grishina)

9.30 | L | Proteomic Dynamics of Aqueous Humor in Uveal Melanoma: a Longitudinal Study and Clinical Correlations (Giulia Midena)

9.45 | L | Assessment of BAP1, PRAME, and CD163 Expression in Relation to Other Tumor Parameters in Uveal Melanoma: A Morphological and Immunohistochemical Study (Michał Jerzy Dopierala)

10.00 | S | Chromosome 8q amplification in the development of UM metastases (Marianna Ambrosio)

10.05 | S | Unusual Ciliochoroidal Tumors (Min Kim)

10.10 | S | Unveiling ocular involvement in leukemia relapse: the crucial role of B-scan ultrasound-A case report (Elvia Mastrogiuseppe)

10.15 | S | Bilateral intraocular involvement of EBV-positive extranodal NK/(T)-cell lymphoma (Alexandra Steinemann)

10.20 | Travel Awards Ceremony

10.30 | Coffee break

UVEAL MELANOMA TREATMENT

Chairs: Iwona Rospond-Kubiak, Gustav Stålhammar

11.00 | L | Real-World Outcomes of Tebentafusp in Metastatic Uveal Melanoma (UM) patients: A Retrospective Cohort Study at Institut Curie (Raphaël Sanchez)

11.15 | L | Impact of Treatment Delays on Survival in Uveal Melanoma: Expanded Cohort and Analytical Approaches (Anna Hagström)

11.30 | L | Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma (Lennart J. Pors)

11.45 | L | Comparative study of ruthenium-106 brachytherapy versus fractionated stereotactic radiotherapy for uveal melanoma (Mike Wu)

12.00 | L | Radiation retinopathy: morpho-functional outcomes after intravitreal treatment with antiVEGF and slow-release dexamethasone implant (Maria Grazia Sammarco)

12.15 | L | Ruthenium-106 Brachytherapy and Central Uveal Melanoma (Luise Grajewski)

12.30 | L | OOG collaborative study on extraocular extension of uveal melanoma - results of historical cohort (Iwona Rospond-Kubiak)

12.45 | L | International Validation of an Improved Classification for Ciliary Body and Choroidal Melanomas Based on Estimation of Tumor Volume (Gustav Stålhammar)

13.00 | Lunch

14:00 | K | Uveal Melanoma: changing paradigms of treatment
Sophie Piperno-Neumann, Institut Curie, Paris, France

OCULAR ONCOLOGY

Chairs: Viktoria Vishnevskia-Dai, Monica Maria Pagliara

14.45 | L | Computer Aided Diagnosis of Eyelid skin tumors Using Machine Learning: Application on Images of Eyelid Skin Lesions (Viktoria Vishnevskia-Dai)

15.00 | L | Mohs micrographic surgery in periocular tumours: a comparison between two decades (Natasha van Poppelers)

15.15 | L | Impact of clinical, histopathological and molecular biomarkers on local and systemic recurrence in patients with conjunctival melanoma (Monica Maria Pagliara)

15.30 | L | Retrospective analysis of a case series of conjunctival melanoma in a national reference center (Ignacio López-Miñarro)

15.45 | L | The Epidemiology of Conjunctival Melanoma in Sweden: A National Cohort Study on Incidence and Trends (Marco A. Lumia Michalski)

16.00 | Coffee break

UVEAL MELANOMA THERAPY, COMPLICATIONS

Chairs: Sophie Piperno-Neumann, Rob Verdijk

16.30 | L | Tumor biopsy as prognostic tool for uveal melanoma patients (Paulina Bartoszek)

16.45 | L | Vision Preservation in Juxta-Foveal Uveal Melanoma After Proton Therapy (Johannes Gollrad)

17.00 | L | Reirradiation of recurrent uveal melanoma following prior proton therapy: clinical efficacy and toxicity outcomes (Ann Schalenbourg)

17.15 | L | Prospective analysis of peripapillary microvasculature with spectral domain optical coherence tomography angiography in patients affected by choroidal melanoma (Francesco Baldo Lanza)

17.30 | L | Long-term clinical outcomes of medium-sized uveal melanomas under observation: a retrospective study (Laura Prieto Domínguez)

17.45 | L | Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma (Matthew O'Riordan)